You are here

Article Text

Article menu

Download PDFPDF

Editorial
NERO: a pilot study but important step towards comprehensive management of obesity hypoventilation syndrome
Free
  1. Jean-Christian Borel1,2,
  2. Anne Laure Borel1,3,
  3. Amanda J Piper4
  1. 1 HP2 laboratory (INSERM U1042), Universite Grenoble Alpes, Grenoble, France
  2. 2 Research and Development Department, AGIRà dom, Non Profit Home Care Provider, Meylan, France
  3. 3 Diabetologia and Nutrition Department, Grenoble University Hospital, Grenoble, France
  4. 4 Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  1. Correspondence to Dr Jean-Christian Borel, AGIR à dom Association, 36 bd des Alpes, Meylan 38240, France; j.borel{at}agiradom.com

https://doi.org/10.1136/thoraxjnl-2017-211032

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The primary goal of treatment for obesity hypoventilation syndrome (OHS) has been to correct sleep-related breathing abnormalities, thereby reversing chronic respiratory failure. Nocturnal non-invasive ventilation (NIV) can achieve this and thus represents the cornerstone of respiratory management for this condition.1–4 While the effectiveness of NIV in improving clinical symptoms and quality of life has been convincingly demonstrated,2 3 5 the mortality rate of patients with OHS treated with NIV remains substantially higher than that of patients with obstructive sleep apnoea.6 Cardiovascular and metabolic comorbidities are the key determinants of a poorer prognosis.6 7 For several years, clinicians have suggested NIV treatment should be integrated into a comprehensive treatment plan that includes lifestyle modification and rehabilitation to further improve outcomes.8–10

    In Thorax, Mandal and colleagues11 report the first randomised controlled trial evaluating the impact of a 3-month inpatient–outpatient multidisciplinary rehabilitation programme in addition to NIV compared with NIV alone in patients with OHS. Since weight loss is obviously the main treatment for OHS, the primary outcome chosen by the authors was change in weight at 12 months. Although no statistical difference between treatment …

    View Full Text

    Linked Articles